Optional product analytics
With your permission, we use privacy-limited analytics to understand which research journeys work. We do not run advertising trackers or session replay. You can change this choice in Preferences. Read the Privacy Policy.
Accelerated statutory enforcement of municipal drinking water standards and industrial wastewater reuse requirements (including EPA PFAS limits) driving Water Quality revenue compounding above 8% annually.
We initiate coverage on Veralto Corporation with a Reduce rating, establishing a fundamental Fair value of USD 79.82 against a report-date price of USD 95.44 on October 8, 2026, representing an implied return of -16.4%,,.3
Our house rating on Veralto Corporation is Reduce. For an ordinary investor, this recommendation indicates trimming existing positions or refraining from committing fresh capital. While Veralto possesses exceptional operational quality and recurring revenue streams across municipal water analytics and packaging quality, the market price has outpaced underlying intrinsic value, leaving equity investors exposed to valuation multiple compression if operating expansion normalizes.
This evaluation was completed at a report-date price of USD 95.44 on October 8, 2026. The house valuation concludes with two public benchmarks: a fundamental Fair value of USD 79.82 and a Potential value ceiling of USD 94.43. At USD 95.44, the shares trade at a 19.6% premium to Fair value, which equates to an implied return of -16.4%, while sitting slightly above the Potential value upper band.3
The primary risk that would fundamentally alter this assessment is a synchronized slowdown in municipal utility procurement and industrial manufacturing across international markets. Water Quality accounts for 60.35% of total revenue ($3,321M in FY2025), and international sales comprise approximately half of the business ($1,505M in High Growth Markets and $1,241M in Western Europe). If public budgetary constraints defer analytical instrument replacements while emerging market industrial demand softens, top-line compounding would decelerate. Fixed corporate SG&A overhead ($1,756M in FY2025) would compress operating margins, lowering annual free cash flow from $1,014M toward $750M-$800M and driving material valuation impairment. Investors would see this deterioration if quarterly Water Quality organic revenue growth decelerates below 2.0% and High Growth Markets revenue turns flat or negative,.5
The strongest catalyst that could support valuation near the Potential value of USD 94.43 is accelerated statutory enforcement of drinking water purity and industrial wastewater discharge standards, particularly strict limits on emerging contaminants such as PFAS. As regulatory mandates tighten, municipal utilities and industrial plants must increase testing frequency and purchase proprietary diagnostic chemistry from Hach and ChemTreat. This dynamic would expand high-margin consumable sales, lift Water Quality operating margins above 25%, and drive consolidated operating margins toward 25.5%, boosting cash generation. However, at the report-date price of USD 95.44, this optimistic development is already fully anticipated by the market,.35
Water Quality generates 60.35% of total revenue ($3,321M in FY2025) and delivers 25.41% operating margins,, supported by non-discretionary municipal drinking water regulations and wastewater compliance requirements.5
Consolidated gross margins of 59.95% outpace industrial peers Xylem (39.24%) and Dover (40.09%), driven by proprietary reagents, test assays, and service contracts representing ~61% recurring revenue across an entrenched installed base.4
With capital expenditures requiring just 1.14% of ($63M in FY2025), Veralto converted 107.9% of into ($1,014M on $940M net income), maintaining strong balance sheet flexibility for bolt-on .
We recommend a Reduce rating on Veralto Corporation because its report-date price of USD 95.44 trades at a 19.6% premium to fundamental Fair value of USD 79.82, offering an unattractive risk-reward profile with -16.4% implied return despite outstanding operational quality,,.3
Veralto Corporation provides essential technology solutions that monitor, enhance, and protect vital resources around the globe. The company operates through two primary reporting segments: Water Quality and Product Quality & Innovation. Through its Water Quality segment, Veralto supplies precision analytics, testing instrumentation, and chemical treatment solutions under leading global brands including Hach, Trojan Technologies, and ChemTreat. These solutions serve municipal utilities and industrial facilities, ensuring drinking water safety and regulatory wastewater compliance.
The Product Quality & Innovation segment enables brand owners and manufacturers to safeguard product integrity and build consumer trust across packaging workflows. Through brands including Videojet, Linx, Esko, X-Rite, and Pantone, the segment provides continuous inkjet printing, laser marking, packaging workflow software, and color measurement systems used across food and beverage, pharmaceuticals, and consumer packaged goods.
A deterministic stress test evaluating concurrent headwinds—a 200 bps deceleration in organic revenue growth, 150 bps operating margin compression from sticky standalone corporate overhead and reagent inflation, and terminal multiple de-rating from 19.96x forward P/E to peer medians of 16.25x (XYL 16.32x, DOV 16.18x)—reduces annual free cash flow from $1,014M in FY2025 toward $750M-$800M. Under these compounded pressures, intrinsic value moves toward the lower valuation bound of $64.83, highlighting material downside risk relative to the share price of $95.44 as of October 8, 2026.
Veralto Corporation possesses a Narrow economic moat grounded in high customer switching costs, regulatory-certified testing methodologies, and a high-margin recurring consumables model. Across its Water Quality segment ($3,321M revenue in FY2025) and Product and Quality Innovation segment ($2,182M revenue), Veralto supplies mission-critical analytics, specialized diagnostic reagents, and automated marking technologies that ensure environmental compliance and product safety. Because testing instrumentation constitutes a negligible fraction of customer operational budgets relative to the immense financial and reputational liabilities of compliance failure, customer retention across municipal utilities and consumer goods packaging lines remains exceptionally high.
The company's competitive advantage is evidenced by its structural gross margin superiority. In FY2025, Veralto delivered a consolidated gross margin of 59.95%, outpacing diversified fluid and industrial peers such as Xylem (39.24%) and Dover (40.09%). This margin premium reflects the razor-and-blade commercial architecture of its core water analytics brands, including Hach and ChemTreat, where proprietary reagents and recurring maintenance generate stable revenue streams that buffer broader economic fluctuations. While information-services compounders such as Verisk operate at higher gross margins (70.18%), Veralto's precision instrumentation and chemistry integration create substantial technical and regulatory moats within physical water testing.
The highlighted cell is Fair value when every assumption sits at its base level ($79.82). Each row and column shows what Fair value becomes when one assumption moves.
Free cash flow to the firm stays positive in the first projected year at $1.0B after modeled reinvestment of $53.8M, with terminal value at 79.1% of enterprise value. A sudden drop in free cash flow is not projected unless capital spending relative to , reinvestment, or resets materially.
Accelerating organic revenue growth in Water Quality and expanding operating margins would indicate that recurring consumable demand and pricing power are compounding faster than modeled. While $95.44 sits above Fair value $79.82, sustained operational outperformance would narrow the valuation gap and justify a more neutral rating.
Capital expenditures represented 1.14% of revenue in FY2025 ($63M capex on $5,503M revenue, following $36M capex in FY2020). The industry operates with low manufacturing capital intensity, as precision assembly, testing, and reagent formulation require modest ongoing physical asset reinvestment. Demand-side capital spending is primarily dictated by municipal utility budgets and industrial client plant expansions.34
The industry cycle expands as global statutory environmental regulations tighten, led by stringent EPA mandates on emerging contaminants like PFAS, European Union water directives, and industrial zero-liquid-discharge compliance requirements. In Product and Quality Innovation, tightening traceability, anti-counterfeiting, and serialized packaging mandates in pharmaceuticals and food manufacturing drive continuous replacement and upgrading of continuous inkjet and laser marking technologies.
A cyclical downshift occurs if municipal tax revenues tighten and municipal debt issuance slows, leading city councils to freeze capital expenditure budgets and delay water utility analytical instrument upgrades. Concurrently, elevated interest rates (such as a 5.27% benchmark yield) and industrial production curtailments in Europe and emerging markets can reduce packaging line throughput, softening ink and marking equipment sales in Product and Quality Innovation.
Veralto is underwritten with a committee rating of Reduce. While business quality and free cash flow generation are strong, the share price of $95.44 as of October 8, 2026 trades at a 19.57% premium to fundamental Fair value of $79.82, yielding an implied return of -16.37%. Investors should maintain an underweight posture or trim existing holdings to reduce downside exposure.3
Portfolio risk management requires capping aggregate exposure to mature compounders trading at premiums above fair value. Given the Reduce rating, position weights should be limited to an underweight threshold of 0-2% of an equity portfolio. Investors should monitor municipal utility bond issuance, federal environmental infrastructure funding disbursements, and industrial production indices across Europe and Asia. Position trimming should be executed methodically to redeploy capital into assets offering positive fundamental asymmetry.
Trading at a 19.6% premium to fundamental Fair value of USD 79.82 and a forward P/E of 19.96x versus the peer median of 16.25x, Veralto offers negative prospective return (-16.4%) and lacks any valuation margin of safety,.3
While Veralto possesses exemplary compounder qualities including a 19.65% ROIC and 59.95% gross margin, new capital commitments at USD 95.44 fail to clear the cost of equity hurdle (8.42% Ke), capping prospective returns and increasing vulnerability to multiple de-rating.
Veralto Corporation is a premier compounder characterized by mission-critical water testing, a 59.95% gross margin, and 107.9% free cash flow conversion. However, the report-date price of USD 95.44 on October 8, 2026 trades at a 19.6% premium to fundamental Fair value of USD 79.82, implying a negative return of -16.4%,. The stock trades at 19.96x forward earnings against the peer median of 16.25x, leaving no margin of safety against public procurement deferrals or emerging market slowdowns.34
Investors should use current valuation strength to reduce holdings toward an underweight allocation. Capital should be redirected toward opportunities with positive upside or preserved in cash until Veralto's market price trades closer to fundamental Fair value of USD 79.82.
Capture your own thesis, position size, and follow-up questions. Stays on this device, only you can see it.
The records this analysis drew on, as they stood when it was run.
A downside scenario materializes if municipal water utilities face severe fiscal constraints and public procurement delays, deferring capital equipment upgrades and tender awards. Simultaneously, industrial retrenchment and macroeconomic softness in High Growth Markets dampen marking and coding shipments in Product and Quality Innovation. Chemical reagent feedstock cost inflation and persistent corporate administrative overhead post-separation compress operating profit margins across both operating divisions. As organic revenue growth slows and return on capital narrows, the valuation premium awarded to the business dissipates, prompting forward earnings multiples to de-rate toward peer benchmarks. Investors would observe this outcome through decelerating organic volume growth in quarterly filings and margin erosion persisting across consecutive quarters through FY2027.
FY2025 consolidated operating margin was 23.21% on $5,503M revenue, generated by Water Quality operating income of $844M and Product and Quality Innovation operating income of $549M. If standalone public company overhead ($1,756M SG&A in FY2025) remains inflexible while chemical reagent feedstocks experience sharp cost inflation that cannot be passed through, a 300 bps operating margin contraction reduces annual operating income by ~$165M, triggering an estimated -18.5% fair value impairment.45
Revenue growth is modeled at 7.41% in FY2026 and 5.69% in FY2027. If High Growth Markets ($1,505M in FY2025) and Western Europe ($1,241M in FY2025) contract due to local fiscal freezes and industrial retrenchment, 5-year revenue CAGR drops 500 bps to below 0.5%, impairing compounding velocity and driving an estimated -24.0% fair value impact.5
The shares trade at a forward P/E of 19.96x as of October 8, 2026 against a peer median forward P/E of 16.25x (Copart at 15.46x, Dover at 16.18x, and Xylem at 16.32x). If compounder quality premia dissipate as organic top-line velocity slows, the modeled terminal P/E of 18.0x contracts 20% to 14.4x, driving an estimated -16.2% fair value impact.23
The five developments that would weaken our investment case.
Gross margin deterioration below 58.00% would demonstrate an inability to offset chemical reagent feedstock and sensor component cost inflation with contractual price increases, impairing the razor-and-blade pricing power moat.
Current:59.95% in FY2025
Alert if<58.00% across two consecutive quarters
Organic revenue expansion slowing below 2.00% would falsify the thesis of non-discretionary municipal water compliance demand, signaling severe municipal budget freezes and prolonged equipment upgrade deferrals.
Current:60.35% of total revenue ($3,321M in FY2025)
Alert if<2.00% annual organic growth over FY2026-FY2027
Zero or negative revenue expansion in High Growth Markets would indicate emerging market industrial retrenchment and persistent currency translation headwinds, undermining geographic diversification benefits.
Current:27.35% of total revenue ($1,505M in FY2025)
Alert if<=0.00% year-over-year revenue growth
SG&A scaling above 32.50% of revenue would confirm sticky standalone corporate overhead and transition service inefficiencies, preventing operating margins from reaching target normalization of 24.0%.
Current:31.91% of revenue ($1,756M in FY2025)
Alert if>32.50% of revenue in FY2026
Free cash flow conversion falling below 85.0% of net income would reveal working capital deterioration or unseasonal channel inventory accumulation, undermining the asset-light compounder thesis.
Current:107.9% of Net Income ($1,014M FCF on $940M Net Income in FY2025),
Moat durability is further sustained by deep integration into public health regulatory architectures. In municipal drinking water and wastewater operations, testing methodologies and diagnostic chemistries are codified into statutory discharge permits and EPA standards. Switching away from Veralto's validated measurement instrumentation requires municipal authorities to undertake complex re-certification and staff re-training procedures, establishing substantial operational switching costs that preserve return on invested capital above 19% across economic cycles.
Veralto generates a return on invested capital of 19.65%, substantially exceeding its computed WACC of 7.9027% and cost of equity of 8.4247%. This generates an economic profit spread exceeding 1,170 bps, reflecting strong capital efficiency supported by asset-light operations where capital expenditures represented just 1.14% of FY2025 revenue ($63M capex on $5,503M revenue).14
Each lens answers a different valuation question. Only included lenses set Fair value; floors and diagnostics provide context.
Project SBC-adjusted EPS, discount each year's earnings at cost of equity, then add a Gordon-growth terminal value.
Under the moderate discount rate, $16.09 comes from forecast-period earnings and $70.43 from the long-term value, totaling $86.52.
Project EPS through the explicit advantage period, fade growth as competition catches up, and discount the full stream at cost of equity.
Apply a terminal P/E to the dated forward EPS path, then discount that future share value back to the analysis date.
Convert the revenue and margin path into after-tax free cash flow, discount the annual per-share amounts and at , then adjust for signed per current share.
Add depreciation to net income, subtract maintenance capex, divide by diluted shares, and apply a normalized valuation multiple.
Multiply the peer median PEG by this stock's forecast growth to derive an implied forward P/E, then apply it to forward EPS.
Solve for the growth rate that makes the model value equal the report-date share price.
The Base scenario establishes Fair value at $79.82, implying a return of -16.4% at a probability of 60.0%. In this modal path, Veralto executes its compounder playbook with mid-single-digit revenue growth driven by the mission-critical replacement of testing consumables, proprietary reagents, and marking inks. Operating margins expand moderately as standalone public company overhead rationalizes and pricing power outpaces input inflation. The business generates exceptional free cash flow conversion on minimal capital expenditure requirements. However, because $95.44 already trades at an elevated forward earnings multiple above peer medians, total returns are restrained by multiple compression toward historical norms. Disconfirmation would occur if organic growth slips below nominal economic growth or if operating margins fail to improve over the FY2026 to FY2027 forecast period.
Under the Bull scenario, with Potential value of $94.43 representing a return of -1.1% at a probability of 20.0%, statutory water quality mandates accelerate globally. Tightening environmental standards for PFAS and micro-pollutants drive double-digit growth in analytical instrumentation and recurring consumable reagents across municipal utilities. Meanwhile, industrial water reuse investments surge and Product and Quality Innovation benefits from stringent pharmaceutical and packaging traceability regulations. Operating leverage through the Veralto Business System expands operating margins beyond historical highs, and disciplined bolt-on acquisitions in water analytics software accelerate earnings growth. This scenario would be disconfirmed if municipal infrastructure disbursements stall or if operating margin expansion plateaus before the conclusion of FY2027.
Meeting consensus expectations confirms the steady compounding of the installed base across Water Quality and Product and Quality Innovation, but leaves the shares trading at $95.44, which remains at a premium to Fair value $79.82 with -16.4% implied return. Valuation multiples remain full relative to peers, warranting a maintained stance.
A revenue or margin shortfall would confirm that municipal procurement delays or international industrial softness are impairing operating leverage. With the stock trading at $95.44, compression of forward multiples toward peer medians would accelerate downside toward Fair value $79.82.
Earnings quality is supported by consistent operating cash flow generation and high recurring revenue from municipal water testing consumables and proprietary chemical reagents. Because testing represents an essential operating expense for statutory compliance, accounts receivable collections remain dependable across municipal and industrial clients. Reported net income translates reliably into free cash flow given minimal capital expenditure requirements for assembly-oriented manufacturing operations. Any divergence between reported operating profit and cash conversion, or an unseasonal build in inventory across European distribution channels, would signal customer procurement deferrals or inventory destocking.
Consensus estimate revisions following recent quarterly disclosures have remained flat across both revenue and diluted earnings projections for FY2026 and FY2027. Sell-side contributors maintained forecasts following quarterly reporting, reflecting steady recurring demand across core water analytics and product identification lines offset by measured municipal capital spending expectations. Forward expectations continue to reflect steady mid-single-digit top-line expansion, leaving earnings momentum balanced without upward revisions to re-rate valuation multiples.
Water Quality generates the majority of consolidated revenue and operating profit through essential testing consumables and reagents; a deceleration would signal municipal budgetary deferrals or industrial water treatment retrenchment, impairing the core compounding thesis.
Operating margins reflect pricing power above cost inflation and efficiency gains from the Veralto Business System; margin compression would indicate corporate overhead stickiness post-separation or inability to pass through chemical reagent cost increases.
Developing regions represent over a quarter of consolidated sales; prolonged industrial weakness or currency depreciation across these regions would compress top-line growth and squeeze international segment returns.
High free cash flow conversion relative to net income validates the asset-light business model; deterioration in working capital or rising capital intensity would reduce cash generation and diminish shareholder return capacity.
Separation from the former parent company established standalone corporate overhead; failure to realize operating leverage on administrative expenses would prevent operating margins from reaching target levels.
| $4.70B |
| $4.87B |
| $5.02B |
| $5.19B |
| $5.50B |
| +4.0% |
| Gross profit | $2.71B | $2.76B | $2.90B | $3.11B | $3.30B | +5.0% |
| Operating income | $1.04B | $1.11B | $1.14B | $1.21B | $1.28B | +5.2% |
| Net income | $861.0M | $845.0M | $839.0M | $833.0M | $940.0M | +2.2% |
| EPS (diluted) | $3.50 | $3.43 | $3.40 | $3.34 | $3.76 | +1.8% |
| EBITDA | $1.15B | $1.20B | $1.21B | $1.28B | $1.35B | +4.1% |
| R&D | $244.0M | $217.0M | $225.0M | $253.0M | $266.0M | +2.2% |
| SG&A | $1.43B | $1.43B | $1.54B | $1.64B | $1.76B | +5.3% |
Cash flow generation is a defining strength of Veralto's compounder model. In FY2025, operating cash flow reached $1,077M, and free cash flow stood at $1,014M after deducting capital expenditures of $63M. Free cash flow conversion relative to net income ($940M) was 107.9%, demonstrating exceptional earnings quality. This continues a multi-year record of strong cash generation, building on $965M of free cash flow in FY2020 from operating cash flow of $1,001M and capex of $36M. The business model's asset-light nature—characterized by low working capital requirements and capex consistently near 1.14% of revenue —ensures that operating profits translate directly into deployable free cash flow.346
Veralto's balance sheet reflects strong liquidity and conservative capital management. As of FY2025, cash and cash equivalents stood at $2,031M against total debt of $3,593M ($2,673M reported balance sheet debt), resulting in modest net debt leverage. Capital allocation is disciplined: internal capital expenditures required only $63M in FY2025, while common dividends consumed $109M, representing a modest 12.59% payout ratio on $940M net income. This capital allocation framework preserves substantial financial flexibility to fund strategic bolt-on acquisitions in digital water software, sensor instrumentation, and packaging quality technologies without compromising balance sheet stability.
Veralto's ROIC of 19.65% reflects superior operational execution, asset-light manufacturing, and high-margin recurring consumable sales. Operating margins across Water Quality (25.41%) and Product and Quality Innovation (25.16%) generate substantial operating profits on a modest invested capital base ($5,778M in FY2025), preserving high returns across business cycles.
Veralto's ROIC of 19.65% compares to a computed WACC of 7.9027% (incorporating an 86.62% equity weight at 8.4247% Ke and 13.38% debt weight at an effective tax rate of 22.15%). The resulting positive economic spread of over 1,170 bps demonstrates substantial value creation above the company's cost of capital.
In FY2025, Water Quality operating profit reached $844M on $3,321M revenue (25.41% margin),, while Product and Quality Innovation generated $549M on $2,182M revenue (25.16% margin),. Consolidated gross margin reached 59.95% on $5,503M revenue.
Consistently high gross and operating margins across both segments confirm strong structural pricing power and operating leverage supported by the Veralto Business System.
Capital expenditures were $63M in FY2025 (1.14% of revenue) and $36M in FY2020, while depreciation was $78M in FY2025. Free cash flow was $1,014M on $940M net income in FY2025.
Minimal capital intensity allows the business to convert over 100% of net earnings into free cash flow, protecting equity holders from capital dilution.
The shares trade at a forward P/E of 19.96x as of October 8, 2026 against peer median forward P/E of 16.25x (XYL 16.32x, DOV 16.18x, CPRT 15.46x).
The stock commands an elevated multiple premium that leaves little margin of safety if organic revenue growth or operating margin expansion falls short of expectations.
| Revenue | $1,474,000,000 |
|---|---|
| Cost of revenue | $572,000,000 |
| Gross profit | $902,000,000 |
| Operating expenses | $587,000,000 |
| Operating income | $315,000,000 |
| Non-operating items and tax | -$74,000,000 |
| Net income | $241,000,000 |
| Total assets | $7,693,000,000 |
|---|---|
| Cash | $2,031,000,000 |
| Current assets | $3,432,000,000 |
| Total liabilities | $4,587,000,000 |
| Current liabilities | $2,056,000,000 |
| Shareholders’ equity | $3,106,000,000 |
| Net income | $940,000,000 |
|---|---|
| Operating inflow | $1,092,000,000 |
| Depreciation and amortization | $78,000,000 |
| Stock-based compensation | $74,000,000 |
| Operating cash flow | $1,077,000,000 |
| Operating outflow | $15,000,000 |
| Cash available | $2,231,000,000 |
| Beginning cash | $1,101,000,000 |
| Exchange-rate effect | $53,000,000 |
| Investing outflow | $98,000,000 |
| Capex | $63,000,000 |
| Other investing activities | $35,000,000 |
| Financing outflow | $102,000,000 |
| Ending cash | $2,031,000,000 |
| Investing cash flow | -$98,000,000 |
| Financing cash flow | -$102,000,000 |
Source: SEC EDGAR · Filed 2026-02-20 · SEC EDGAR
| Revenue by operating segment | Revenue | Share | YoY |
|---|---|---|---|
| Water Quality | $3.3B | 60.3% | 5.8% |
| Product And Quality Innovation | $2.2B | 39.7% | 6.2% |
Source: SEC EDGAR · Filed 2026-02-20 · SEC EDGAR
| Revenue by geography | Revenue | Share | YoY |
|---|---|---|---|
| North America | $2.6B | 48% | 5.9% |
| High Growth Markets | $1.5B | 27.3% | 4.8% |
| Western Europe | $1.2B | 22.6% | 8% |
| Other Developed Markets | $118M | 2.1% | 2.6% |
Point-in-time financial data used in the 2026-10-08 analysis.
| Period | Revenue | EBITDA | Net income | Operating cash flow | Free cash flow | Capex | Depreciation and amortization | Stock-based compensation | Share repurchases | Dividends paid | Net debt issuance | Investing cash flow | Financing cash flow | Beginning cash | Ending cash | Cash and investments | Total debt | Operating margin | ROIC | WACC | ROIC − WACC spread |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2020-12-31 | $4.3B | $1.1B | $724M | $1B | $965M | $36M | $110M | $30M | — | — | — | -$157M | -$844M | — | $0 | $0 | — | 21.9% | — | — | — |
| 2021-12-31 | $4.7B | $1.1B | $861M | $896M | $842M | $54M | $106M | $34M | — | — | — | -$97M | -$799M | $0 | $0 | $0 | $135M | 22.1% | — | — | — |
| 2022-12-31 | $4.9B | $1.2B | $845M | $870M | $836M | $34M | $90M | $41M | $781M | $0 | $0 | -$89M | -$781M | $0 | $0 | $0 | $0 | 22.8% | — | — | — |
| 2023-12-31 | $5B | $1.2B | $839M | $963M | $909M | $54M | $87M | $55M | $147M | $0 | $2.6B | -$55M | -$135M | $0 | $762M | $762M | $2.6B | 22.7% | — | 6.6% | — |
| 2024-12-31 | $5.2B | $1.3B | $833M | $875M | $820M | $55M | $78M | $65M | $0 | $89M | $0 | -$434M | -$65M | $762M | $1.1B | $1.1B | $2.6B | 23.3% | — | 7.4% | — |
| 2025-12-31 | $5.5B | $1.3B | $940M | $1.1B | $1B | $63M | $78M | $74M | $0 | $109M | $0 | -$98M | -$102M | $1.1B | $2B | $2B | $2.7B | 23.2% | — | 6.5% | — |
Veralto Corporation (VLTO) trades at 20.0x forward earnings against a peer median of 16.2x. Its EV/EBITDA of 17.9x compares with a peer median of 13.6x. The comparison uses 4 peers: Verisk Analytics Inc., Xylem Inc., Copart Inc. and Dover Corporation, as of 2026-10-08.
Veralto commands leadership positions in water analytics and packaging traceability. Through Hach, Trojan Technologies, and ChemTreat, Veralto maintains leading market share in municipal water testing and industrial water treatment. Through Videojet, Linx, Esko, and Pantone, the company commands strong positioning in commercial packaging design, brand color consistency, and production-line code application, giving it entrenched customer relationships across stable, non-cyclical end markets.
| Action |
|---|
| Why |
|---|
| <$80.00 | Maintain watchlist status only; evaluate initial accumulation only if valuation reaches parity with Fair value. | Aligns market price with fundamental Fair value of $79.82, eliminating the current 19.57% market valuation premium. |
| <$72.00 | Begin building a core compounder allocation if valuation offers an adequate margin of safety. |
Long-term investors with significant taxable capital gains may hold a reduced core position given the durability of the recurring consumables model (~61% recurring revenue), but should trim over-allocated exposures on any strength above the Potential value ceiling of USD 94.43.
Not every cited input appears here: internal calculations and intermediate model outputs have no external record, and some citations could not be matched to one.
Alert if<85.0% on a trailing 12-month basis
Discounted forecast-period cash flows ($18.08) plus discounted terminal value ($68.25) minus signed net debt per current share ($2.63) equals the $83.70 lens value shown above. Negative net debt is net cash, so subtracting it raises value.
Project revenue, apply a terminal EV/revenue multiple, discount enterprise value, subtract net debt, and divide by diluted shares.
| XYL |
| Xylem Inc. |
| $23.7B |
| 16.3x |
| 2.6x |
| 13.0x |
| 9.2% |
| 17.0% |
| CPRT | Copart Inc. | $25.1B | 15.5x | 5.4x | 10.9x | 16.2% | 32.0% |
| DOV | Dover Corporation | $25.4B | 16.2x | 3.0x | 14.1x | 14.9% | 18.7% |
